NEW YORK, NY / ACCESSWIRE / March 17, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Nutanix, Inc. (NASDAQ:NTNX)
Class Period: March 1, 2018 - May 30, 2019
Lead Plaintiff Deadline: March 22, 2021
During the class period, Nutanix, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: Nutanix had materially overstated its customer base and sales productivity, and that such overstatements would eventually cause the Company's stock price to drop dramatically.
Learn about your recoverable losses in NTNX: http://www.kleinstocklaw.com/pslra-1/nutanix-inc-loss-submission-form?id=13754&from=1
Astrazeneca Plc (NYSE:AZN)
Class Period: May 21, 2020 - November 20, 2020
Lead Plaintiff Deadline: March 29, 2021
Astrazeneca Plc allegedly made materially false and/or misleading statements and/or failed to disclose that: (a) initial clinical trials for the Company's COVID-19 vaccine, AZD1222, had suffered from a critical manufacturing error, resulting in a substantial number of trial participants receiving half the designed dosage; (b) clinical trials for AZD1222 consisted of a patchwork of disparate patient subgroups, each with subtly different treatments, undermining the validity and import of the conclusions that could be drawn from the clinical data across these disparate patient populations; (c) certain clinical trial participants for AZD1222 had not received a second dose at the designated time points, but rather received the second dose up to several weeks after the dose had been scheduled to be delivered according to the original trial design; (d) AstraZeneca had failed to include a substantial number of patients over 55 years of age in its clinical trials for AZD1222, despite this patient population being particularly vulnerable to the effects of COVID-19 and thus a high priority target market for the drug; (e) AstraZeneca's clinical trials for AZD1222 had been hamstrung by widespread flaws in design, errors in execution, and a failure to properly coordinate and communicate with regulatory authorities and the general public; (f) as a result of (a)-(e) above, the clinical trials for AZD1222 had not been conducted in accordance with industry best practices and acceptable standards and the data and conclusions that could be derived from the clinical trials was of limited utility; and (g) as a result of (a)-(f) above, AZD1222 was unlikely to be approved for commercial use in the United States in the short term, one of the largest potential markets for the drug.
Learn about your recoverable losses in AZN: http://www.kleinstocklaw.com/pslra-1/astrazeneca-plc-loss-submission-form?id=13754&from=1
Infinity Q Diversified Alpha Fund Institutional Class (NASDAQ:IQDNX)
Class Period: December 21, 2018 - February 22, 2021
Lead Plaintiff Deadline: April 27, 2021
According to the complaint, Infinity Q Diversified Alpha Fund Institutional Class allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Infinity Q's Chief Investment Officer made adjustments to certain parameters within the third-party pricing model that affected the valuation of the swaps held by the Fund; (2) consequently, Infinity Q would not be able to calculate NAV correctly; (3) as a result, the previously reported NAVs were unreliable; (4) because of the foregoing, the Fund would halt redemptions and liquidate its assets; and (5) as a result, the Prospectuses were materially false and/or misleading and failed to state information required to be stated therein.
Learn about your recoverable losses in IQDNX: http://www.kleinstocklaw.com/pslra-1/infinity-q-diversified-alpha-fund-loss-submission-form?id=13754&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE: The Klein Law Firm